BROOKLYN, N.Y., March 14, 2024 /PRNewswire/ -- Calder Biosciences, Inc., a next-generation vaccine company, has been published in a Nature Communications article (https://www.nature.com/articles/s41467-024-46295-8) that debuts and validates the application of Calder's '3D Vaxlock' platform technology.

纽约布鲁克林，2024年3月14日/PRNewswire/--下一代疫苗公司Calder Biosciences，Inc.，已在《自然通讯》的一篇文章中发表(https://www.nature.com/articles/s41467-024-46295-8)这首次展示并验证了Calder的“3D Vaxlock”平台技术的应用。

When applied to the Respiratory Syncytial Virus (RSV) F protein as a vaccine immunogen, Calder's 3D Vaxlock technology achieves an unprecedented 11X more potent immune response than the standard industry comparator. .

当应用于呼吸道合胞病毒（RSV）F蛋白作为疫苗免疫原时，Calder的3D Vaxlock技术实现了前所未有的比标准行业比较器更强11倍的免疫应答。。

Application of the technology not only dramatically improves potency, but also improves shelf-life of the vaccine at refrigerated temperatures that will facilitate distribution and delivery. The 11-fold higher responses are measured in terms of antibodies generated that neutralize the virus on contact, thus preventing infection.

该技术的应用不仅大大提高了效力，而且还提高了疫苗在冷藏温度下的保质期，这将有助于分发和交付。根据产生的抗体来衡量高11倍的反应，这些抗体在接触时中和病毒，从而防止感染。

Calder's vaccine also demonstrates improvements in the quality of immune responses elicited, since a greater proportion of the antibodies produced neutralize the virus..

Calder的疫苗还显示出引发的免疫反应质量的改善，因为产生的抗体中有更大比例可以中和病毒。。

2023 was an exciting year for developments in preventing RSV, given the groundbreaking achievements of GSK and Pfizer in gaining licensure of the first-ever RSV vaccines, Arexvy and Abrysvo, for use in the elderly and maternal vaccination. While these licensures have already done a great deal to bolster human health, the published data suggest that adults over 75 represent a patient population that could benefit greatly from additional potency improvements..

考虑到葛兰素史克公司和辉瑞公司在获得用于老年人和产妇疫苗接种的第一种RSV疫苗Arexvy和Abrysvo的许可证方面取得了开创性的成就，2023年是预防RSV发展的激动人心的一年。虽然这些许可证已经为促进人类健康做了大量工作，但公布的数据表明，75岁以上的成年人代表了一个可以从额外的效力改进中受益匪浅的患者群体。。

'There remains an urgent need for vaccines that provide 75+ older adults and the frail good protection. And protecting newborn children for a longer period through maternal vaccination also remains an important goal,' said Florian Schödel, MD, a member of Calder's Scientific Advisory Board. In the Nature Communications manuscript, Calder demonstrates that a high dose of their RSV vaccine achieves responses in aged, immunosenescent animals equivalent to responses in the young animal control group.     .

“仍然迫切需要能够为75多名老年人和体弱者提供良好保护的疫苗。考尔德科学咨询委员会成员、医学博士弗洛里安·舍德尔（FlorianSchdel）说，通过母亲接种疫苗来保护新生儿更长时间仍然是一个重要目标。在《自然通讯》手稿中，考尔德证明，高剂量的RSV疫苗在老年免疫衰老动物中获得的反应相当于年轻动物对照组的反应。。

Calder's 3D Vaxlock technology engineers zero-length carbon-carbon bonds between tyrosine residues in target vaccine immunogens.  This technology combines structure-based design and a novel bioprocess, and the bonds are site-specific and targeted to preserve the 3D shape of a protein in the regions that elicit the best immune responses, achieving best-in-class protection..

Calder的3D Vaxlock技术设计了靶疫苗免疫原中酪氨酸残基之间的零长碳-碳键。这项技术结合了基于结构的设计和一种新颖的生物过程，这些键是位点特异性的，有针对性地在引起最佳免疫反应的区域保留蛋白质的3D形状，从而实现最佳的保护。。

'A new stabilization technology as clean and precise as this one is exactly what's needed to unlock the full potential of protein vaccines,' Calder's co-founder and CEO Chris Marshall stated to describe the potential of the technology. Unlike disulfide bonds, dityrosine bonds are irreversible, and their formation is catalyzed after the protein is fully folded in its native state..

考尔德的联合创始人兼首席执行官克里斯·马歇尔（ChrisMarshall）在描述这项技术的潜力时表示：“像这项技术这样干净而精确的新稳定技术正是释放蛋白质疫苗全部潜力所需要的。”。与二硫键不同，二酪氨酸键是不可逆的，它们的形成是在蛋白质以其天然状态完全折叠后催化的。。

In addition to the RSV program, Calder is applying its technology to Universal Influenza and Epstein-Barr virus vaccines. 'On the heels of the Covid pandemic, the benefits of vaccination for human health are incontrovertible. Our technology is going to revolutionize the vaccine space, making vaccines that are even safer and more potent,' said Calder's co-founder and CSO, Mark Yondola, who is also the senior author on the paper.

除了RSV项目外，考尔德还将其技术应用于通用流感和爱泼斯坦-巴尔病毒疫苗。”在新型冠状病毒大流行之后，疫苗接种对人类健康的益处是无可争议的。“我们的技术将彻底改变疫苗领域，使疫苗更安全、更有效，”卡尔德的联合创始人兼CSO马克·扬多拉（Mark Yondola）说，他也是该论文的资深作者。

Calder also plans to apply its technology more generally in protein engineering, imparting thermostability as needed to additional subunit vaccines, biologics, or other targets..

考尔德还计划将其技术更广泛地应用于蛋白质工程，根据需要为其他亚单位疫苗、生物制剂或其他靶标赋予热稳定性。。

Contact: yondola@calderbiosciences.com

联系yondola@calderbiosciences.com

SOURCE Calder Biosciences Inc.

SOURCE Calder生物科学公司。